Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Colorcon
Mallinckrodt
Deloitte
Citi
McKinsey
Farmers Insurance
Cerilliant
Novartis

Generated: August 17, 2017

DrugPatentWatch Database Preview

Relypsa Inc Company Profile

« Back to Dashboard

What is the competitive landscape for RELYPSA INC, and what generic alternatives to RELYPSA INC drugs are available?

RELYPSA INC has one approved drug.

There are ten US patents protecting RELYPSA INC drugs.

There are one hundred and twenty-four patent family members on RELYPSA INC drugs in twenty-one countries.

Summary for Applicant: Relypsa Inc

Patents:10
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Relypsa Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,282,960Ion binding compositions► Subscribe
7,429,394Ion binding compositions► Subscribe
8,409,561Methods and compositions for treatment of ion imbalances► Subscribe
7,776,319Methods and compositions for treatment of ion imbalances► Subscribe
8,445,014Ion binding compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Relypsa Inc Drugs

Country Document Number Estimated Expiration
Japan5756403► Subscribe
World Intellectual Property Organization (WIPO)2010022381► Subscribe
United Kingdom201222749► Subscribe
Australia2010214729► Subscribe
China104822383► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Novartis
Colorcon
McKesson
Cantor Fitzgerald
Cipla
Healthtrust
Chubb
Deloitte
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot